← Back to patent-cliff list
TB511
Tier C — Watch / tradeTB511
Twinpig Biolab Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：ITGB2
Indications (approved)：Non-small cell lung cancer, Hepatocellular carcinoma, Colorectal cancer, Prostate cancer, Castration-resistant prostate cancer, 三阴性乳腺癌, Solid tumour, Pancreatic cancer
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TB511?
Approved indications include: Non-small cell lung cancer, Hepatocellular carcinoma, Colorectal cancer, Prostate cancer, Castration-resistant prostate cancer, 三阴性乳腺癌, Solid tumour, Pancreatic cancer.
When does the TB511 patent expire?
No public expiry year is available for TB511 yet; this page updates once verified.
How do I get a quote for TB511 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22